Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT DISKUS 50 versus QNASL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT DISKUS 50 versus QNASL.
FLOVENT DISKUS 50 vs QNASL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; anti-inflammatory transcription factor modulation; inhibits phospholipase A2, reduces arachidonic acid release, decreases prostaglandin and leukotriene synthesis; suppresses cytokine production and inflammatory cell migration.
Beclomethasone dipropionate is a corticosteroid with anti-inflammatory activity. It binds to glucocorticoid receptors, inhibiting inflammatory mediators such as prostaglandins and leukotrienes, and reducing nasal inflammation.
1 inhalation (50 mcg) twice daily, administered via oral inhalation.
1 to 2 sprays (80 mcg/spray) per nostril once daily; maximum 2 sprays/nostril/day.
None Documented
None Documented
Terminal elimination half-life is approximately 14-17.5 hours; this supports once- or twice-daily dosing in asthma maintenance.
The terminal elimination half-life is approximately 8-10 hours in healthy adults, supporting twice-daily administration for systemic effects; however, intranasal administration results in minimal systemic absorption, and local half-life in nasal tissues is not well characterized.
Primarily fecal (87-90%) after hepatic metabolism; renal excretion accounts for <5% as unchanged drug and metabolites.
The majority of a dose (approximately 40-50%) is excreted in feces as unchanged drug and metabolites, with about 10-15% excreted in urine as metabolites. Biliary excretion is the primary route of elimination.
Category C
Category C
Corticosteroid
Corticosteroid